Essentials · Evidence reviewed
Can GLP-1 medicines affect birth control or pregnancy plans?
Pregnancy planning and contraception are easy to overlook when comparing weight-loss medicines. Eli Lilly's FDA prescribing information for tirzepatide, marketed as Zepbound, includes specific warnings about pregnancy and oral hormonal contraceptives. These instructions are important because not all medicines have identical interaction rules.
Why does the Zepbound label mention birth control?
Tirzepatide delays stomach emptying, which can affect absorption of medicines taken by mouth. The label advises people using oral hormonal contraception to switch to a non-oral method or add a barrier method for four weeks after starting Zepbound and for four weeks after every dose increase.
Does this apply to all contraception?
The Zepbound labeling says non-oral hormonal contraceptives should not be affected by this stomach-emptying mechanism. The right method depends on personal circumstances and should be discussed with a clinician or pharmacist.
What if someone becomes pregnant?
The label advises stopping Zepbound when pregnancy is recognized because weight loss offers no benefit during pregnancy and the medicine may cause fetal harm. Contact the prescribing team promptly rather than making assumptions about risk.
Is this the same for every GLP-1 medicine?
No. Individual products have different warnings and recommended precautions. Never copy one product's pregnancy timing or contraceptive advice to another medicine without checking its specific FDA label.
What should you ask before treatment?
Tell your clinician if you are pregnant, could become pregnant, are planning pregnancy, breastfeeding or using oral contraception. Ask about the exact product and timing appropriate for your plans.
The bottom line
Ask about pregnancy and contraception before treatment or dose changes; follow the specific product label.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-08-28. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceZepbound FDA prescribing information ↗
This guide explains published evidence; source dates may be older than the review date. Our interpretation is educational and does not replace medical or insurance advice.